Atrial Flutter Ablation in the iCMR

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Imricor Medical Systems
Study ID
NCT05904548
Status
Recruiting

Conditions

  • Atrial Flutter Typical

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RF Ablation — DEVICE
    RF ablation for type I atrial flutter under iCMR guidance

Study Details

The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

Key Dates

Start date
Jun 20, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
91 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vision-MR Atrial Flutter Ablation
    Type 1 Atrial Flutter ablation performed in the iCMR with the Vision-MR Ablation Catheter 2.0 and associated Advantage-MR EP recorder and stimulator system.

Primary Outcome Measure

Primary Safety Endpoint: Composite of serious cardiovascular adverse events [ Time Frame: 7-days post procedure ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Johns Hopkins University (JHU)BaltimoreMaryland21218
Aravindan Kolandaivelu, MD (PRINCIPAL_INVESTIGATOR)
University of Virginia (UVA)CharlottesvilleVirginia22903
Kenneth Bilchick, MD (PRINCIPAL_INVESTIGATOR)
Virginia Commonwealth UniversityRichmondVirginia23284
Ajay Pillai, M.D.
478-957-2109
Ajay Pillai, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD